The third indication under the central nervous system therapeutic program will involve drugs to treat Parkinson's Disease. The lack of therapeutic options with different mechanisms of action to treat mild and moderate symptoms related to Parkinson's Disease, and the significant adverse effects associated with current chronic medications, highlight the urgent and critical importance of this effort.